Pancreatic Cancer Research

ResearcherQingdao UniversityActive in the last 2 years

Wantao Ying

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8309-2198; OpenAlex author ID A5014926288. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
6
Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 4

  1. In-Depth Plasma Proteomics Identifies SNCA as a Discriminating Biomarker of PDAC. Last author DOI 10.1021/acs.jproteome.5c01286↗
  2. Core-fucosylated glycoproteins as biomarkers for diagnosing pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ijbiomac.2025.146774↗
  3. Integrative proteomics and n-glycoproteomics reveal the synergistic anti-tumor effects of aspirin- and gemcitabine-based chemotherapy on pancreatic cancer cell… Last author DOI 10.1007/s13402-023-00856-z↗
  4. Pancreatic cancer cells spectral library by DIA-MS and the phenotype analysis of gemcitabine sensitivity. Last author DOI 10.1038/s41597-022-01407-1↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ran Kong · 2 shared papers, 2022–2024 · strength 0.49
  2. Chunyi Hao · 1 shared paper, 2025 · strength 0.28
  3. Jianhui Wu · 1 shared paper, 2025 · strength 0.28
  4. Xinyu Zhao · 1 shared paper, 2025 · strength 0.28
  5. Jiaqi Yu · 1 shared paper, 2026 · strength 0.27
  6. Xiaoyu Li · 1 shared paper, 2024 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.